COVID-19 Due Diligence Checklist for
Life Sciences and Healthcare Transactions

Navigate, Negotiate and Close Your Transactions During COVID-19.

In the best of times, business collaborations are exciting, complex and challenging. During the COVID-19 era, investments, alliances, acquisitions and other partnerships face a host of unique requirements—and offer high-potential opportunities.

To maximize the value of business collaborations, investors, corporations and other organizations need clarity, even when clarity seems impossible. That’s where McDermott and Collaborative Transformation come in.

The team at McDermott has unmatched experience navigating the business and legal needs that arise during health and life sciences collaborations. Our special brand of legal acumen, rooted in decades of experience and powered by bold original thinking, is calibrated to overcome challenges and propel your success.

To help your collaborations and investments thrive during this time, we’ve created the COVID-19 due diligence checklist. The detailed questions will help you navigate, negotiate and close current and forthcoming deals.

Our report includes specific, COVID-19-focused questions in the following areas:

  • Corporate Organization and Management
  • Securities and Ownership
  • Financial Matters
  • Taxation
  • Company Contracts and Agreements
  • Operations and Business Continuity Matters
  • Employment and Employee Benefits
  • Real Property
  • Insurance
  • Information Technology, Privacy, and Cybersecurity
  • Regulatory
  • Lobbying and Foreign Agents Registration Act

Access your checklist.



By submitting this form, you agree to consent to processing and accept the terms of our privacy policy.

XING


Related Site:     McDermott+ Consulting

Attorney Advertising ©2021 McDermott Will & Emery